Novozymes A/S (NVZMY) Short Interest Ratio & Short Volume $58.47 +0.74 (+1.28%) As of 03/28/2025 03:59 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock Novozymes A/S Short Interest DataNovozymes A/S (NVZMY) has a short interest of 1,700 shares, representing 0.00% of the float (the number of shares available for trading by the public). This marks a 1,600.00% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 19,406 shares to cover all short positions.Current Short Interest1,700 sharesPrevious Short Interest100 sharesChange Vs. Previous Month+1,600.00%Dollar Volume Sold Short$102,663.00Short Interest Ratio0.1 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares468,299,000 sharesShort Percent of Float0.00%Today's Trading Volume22,273 sharesAverage Trading Volume19,406 sharesToday's Volume Vs. Average115% Short Selling Novozymes A/S? Sign up to receive the latest short interest report for Novozymes A/S and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNVZMY Short Interest Over TimeNVZMY Days to Cover Over TimeNVZMY Percentage of Float Shorted Over Time Remove Ads Novozymes A/S Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20251,700 shares $102,663.00 +1,600.0%0.0%0.1 $60.39 2/28/2025100 shares $6,027.00 No Change0.0%0 $60.27 2/15/2025100 shares $5,835.00 No Change0.0%0 $58.35 1/31/2025100 shares $5,719.00 -98.6%N/A0 $57.19 1/15/20257,300 shares $403,033.00 -83.3%N/A0.1 $55.21 12/31/202443,700 shares $2.47 million +680.4%N/A1 $56.54 12/15/20245,600 shares $328,468.00 +1,020.0%N/A0.2 $58.66 11/30/2024500 shares $29,375.00 +150.0%N/A0 $58.75 11/15/2024200 shares $11,310.00 -83.3%N/A0 $56.55 10/31/20241,200 shares $75,288.00 -14.3%N/A0.1 $62.74 Get the Latest News and Ratings for NVZMY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter. 10/15/20241,400 shares $95,382.00 -22.2%N/A0.1 $68.13 9/30/20241,800 shares $129,618.00 -73.5%N/A0.1 $72.01 9/15/20246,800 shares $473,620.00 +13.3%N/A0.5 $69.65 8/31/20246,000 shares $415,380.00 +172.7%N/A0.3 $69.23 8/15/20242,200 shares $141,042.00 +57.1%N/A0.1 $64.11 7/31/20241,400 shares $89,208.00 -83.3%N/A0.1 $63.72 7/15/20248,400 shares $524,580.00 +33.3%N/A0.5 $62.45 6/30/20246,300 shares $384,741.00 +125.0%N/A0.2 $61.07 6/15/20242,800 shares $163,380.00 +27.3%N/A0.1 $58.35 5/31/20242,200 shares $131,362.00 -8.3%N/A0.1 $59.71 5/15/20242,400 shares $149,208.00 +2,300.0%N/A0.1 $62.17 4/30/2024100 shares $5,513.00 -85.7%N/A0 $55.13 4/15/2024700 shares $38,115.07 -56.3%N/A0 $54.45 3/31/20241,600 shares $94,176.00 -55.6%N/A0.1 $58.86 3/15/20243,600 shares $214,200.00 +176.9%N/A0.1 $59.50 2/29/20241,300 shares $73,307.00 -79.7%N/A0 $56.39 2/15/20246,400 shares $341,696.00 +128.6%N/A0.2 $53.39 1/15/20241,900 shares $102,448.00 -9.5%N/A0.1 $53.92 12/31/20232,100 shares $115,300.50 +320.0%N/A0.1 $54.91 12/15/2023500 shares $26,030.00 -61.5%N/A0 $52.06 11/30/20231,300 shares $67,470.00 -93.4%N/A0 $51.90 11/15/202319,700 shares $1.02 million +271.7%N/A0.4 $51.76 10/31/20235,300 shares $238,606.00 +140.9%N/A0.1 $45.02 10/15/20232,200 shares $90,772.00 -81.5%N/A0 $41.26 9/30/202311,900 shares $478,499.00 +600.0%N/A0.1 $40.21 9/15/20231,700 shares $72,352.00 +88.9%N/A0 $42.56 8/31/2023900 shares $39,024.00 -72.7%N/A0 $43.36 8/15/20233,300 shares $151,800.00 -56.6%N/A0.1 $46.00 7/31/20237,600 shares $380,988.00 +590.9%N/A0.4 $50.13 7/15/20231,100 shares $54,868.00 -8.3%N/A0 $49.88Musk’s real agenda in D.C. (Ad)In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…Here’s the full story. 6/30/20231,200 shares $55,860.00 -40.0%N/A0 $46.55 6/15/20232,000 shares $99,680.00 -65.5%N/A0.1 $49.84 5/31/20235,800 shares $279,328.00 +70.6%N/A0.2 $48.16 5/15/20233,400 shares $181,492.00 +88.9%N/A0.1 $53.38 4/30/20231,800 shares $93,600.00 +125.0%N/A0 $52.00 4/15/2023800 shares $40,592.00 -83.7%N/A0 $50.74 3/31/20234,900 shares $250,341.00 +1,533.3%N/A0.2 $51.09 3/15/2023300 shares $14,337.00 -25.0%N/A0 $47.79 2/28/2023400 shares $19,196.00 -42.9%N/A0 $47.99 2/15/2023700 shares $35,217.00 No ChangeN/A0 $50.31 1/31/2023700 shares $36,253.00 -86.3%N/A0 $51.79 1/15/20235,100 shares $260,916.00 +920.0%N/A0.1 $51.16 12/30/2022500 shares $25,230.00 -44.4%N/A0 $50.46 12/15/2022900 shares $46,854.00 -47.1%N/A0 $52.06 11/30/20221,700 shares $98,243.00 +30.8%N/A0.1 $57.79 11/15/20221,300 shares $74,262.50 +8.3%N/A0 $57.13 10/31/20221,200 shares $62,767.20 +100.0%N/A0 $52.31 10/15/2022600 shares $28,674.00 -85.0%N/A0 $47.79 9/30/20224,000 shares $200,200.00 -4.8%N/A0.1 $50.05 9/15/20224,200 shares $222,642.00 +223.1%N/A0.1 $53.01 8/31/20221,300 shares $74,412.00 +62.5%N/A0 $57.24 8/15/2022800 shares $50,840.00 -83.0%N/A0 $63.55 7/31/20224,700 shares $300,391.10 -48.4%N/A0.1 $63.91 7/15/20229,100 shares $533,442.00 +550.0%N/A0.2 $58.62 6/30/20221,400 shares $84,042.00 -39.1%N/A0 $60.03 6/15/20222,300 shares $130,686.00 -87.1%N/A0.1 $56.82 5/31/202217,800 shares $1.13 million +143.8%N/A0.5 $63.51 5/15/20227,300 shares $439,095.00 -53.5%N/A0.2 $60.15 4/30/202215,700 shares $1.09 million +76.4%N/A0.6 $69.57 4/15/20228,900 shares $598,169.00 +56.1%N/A0.4 $67.21 3/31/20225,700 shares $391,020.00 +216.7%N/A0.2 $68.60 3/15/20221,800 shares $107,298.00 +50.0%N/A0 $59.61 2/28/20221,200 shares $78,132.00 -7.7%N/A0 $65.11 2/15/20221,300 shares $79,014.00 -79.4%N/A0 $60.78 1/31/20226,300 shares $431,550.00 -38.2%N/A0.1 $68.50 1/15/202210,200 shares $733,278.00 +17.2%N/A0.4 $71.89 12/31/20218,700 shares $723,144.00 +67.3%N/A0.3 $83.12 12/15/20215,200 shares $414,362.00 -1.9%N/A0.2 $79.69 11/30/20215,300 shares $401,316.00 -37.7%N/A0.3 $75.72 11/15/20218,500 shares $670,480.00 +51.8%N/A0.5 $78.88 10/29/20215,600 shares $412,944.00 +330.8%N/A0.3 $73.74 10/15/20211,300 shares $91,331.50 -81.9%N/A0.1 $70.26 9/30/20217,200 shares $492,480.00 +24.1%N/A0.4 $68.40 9/15/20215,800 shares $437,088.00 +262.5%N/A0.4 $75.36 8/31/20211,600 shares $129,536.00 -44.8%N/A0.1 $80.96 8/13/20212,900 shares $227,084.50 +262.5%N/A0.3 $78.31 7/30/2021800 shares $62,560.00 -79.5%N/A0.1 $78.20 7/15/20213,900 shares $295,893.00 +44.4%N/A0.3 $75.87 6/30/20212,700 shares $203,634.00 -57.1%N/A0.1 $75.42 6/15/20216,300 shares $466,137.00 -66.8%N/A0.3 $73.99Musk’s real agenda in D.C. (Ad)In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…Here’s the full story. 5/28/202119,000 shares $1.39 million +280.0%N/A1.1 $73.23 5/14/20215,000 shares $364,800.00 +257.1%N/A0.3 $72.96 4/30/20211,400 shares $100,436.00 -78.5%N/A0.1 $71.74 4/15/20216,500 shares $427,310.00 -54.9%N/A0.3 $65.74 3/31/202114,400 shares $911,232.00 -30.8%N/A0.8 $63.28 3/15/202120,800 shares $1.31 million +845.5%N/A0.9 $62.88 2/26/20212,200 shares $137,258.00 -12.0%N/A0.1 $62.39 2/12/20212,500 shares $164,750.00 -56.9%N/A0.1 $65.90 1/29/20215,800 shares $352,988.00 +75.8%N/A0.3 $60.86 1/15/20214,200 shares $244,524.00 +61.5%N/A0 $58.22 12/31/20209,500 shares $545,395.00 +126.2%N/A0.4 $57.41 12/15/20204,200 shares $232,848.00 +61.5%N/A0 $55.44 11/30/20202,600 shares $149,916.00 +100.0%N/A0.1 $57.66 11/15/20201,300 shares $77,427.35 -81.9%N/A0.1 $59.56 10/30/20207,200 shares $441,792.00 +20.0%N/A0.4 $61.36 10/15/20206,000 shares $387,240.00 +106.9%N/A0.4 $64.54 9/30/20202,900 shares $182,526.00 -35.6%N/A0.2 $62.94 9/15/20204,500 shares $293,490.00 +55.2%N/A0 $65.22 8/31/20202,900 shares $170,969.50 +107.1%N/A0.1 $58.96 8/14/20201,400 shares $80,422.30 -39.1%N/A0.1 $57.44 7/31/20202,300 shares $136,505.00 -63.5%N/A0.1 $59.35 7/15/20206,300 shares $382,095.00 +80.0%N/A0.3 $60.65 6/30/20203,500 shares $202,405.00 +218.2%N/A0.1 $57.83 6/15/20201,100 shares $61,974.00 +57.1%N/A0 $56.34 5/29/2020700 shares $38,311.00 -83.3%N/A0 $54.73 5/15/20204,200 shares $211,260.00 +20.0%N/A0.1 $50.30 4/30/20203,500 shares $170,450.00 +3,400.0%N/A0.1 $48.70 4/15/2020100 shares $4,543.00 -100.0%N/A0 $45.43 3/31/2020367,900 shares $16.98 million +2,171.0%N/A1.2 $46.15 NVZMY Short Interest - Frequently Asked Questions What is Novozymes A/S's current short interest? Short interest is the volume of Novozymes A/S shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 1,700 shares of NVZMY short. 0.00% of Novozymes A/S's shares are currently sold short. Learn More on Novozymes A/S's current short interest. What is a good short interest percentage for Novozymes A/S? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Novozymes A/S's floating shares are currently sold short. Is Novozymes A/S's short interest increasing or decreasing? Novozymes A/S saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,700 shares, an increase of 1,600.0% from the previous total of 100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Novozymes A/S's short interest compare to its competitors? 0.00% of Novozymes A/S's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Novozymes A/S: argenx SE (3.76%), BioNTech SE (1.36%), Biogen Inc. (2.27%), Moderna, Inc. (13.72%), Neurocrine Biosciences, Inc. (3.45%), Exelixis, Inc. (4.85%), Bio-Techne Co. (4.13%), Vaxcyte, Inc. (10.44%), Qiagen (1.72%), Halozyme Therapeutics, Inc. (8.25%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Novozymes A/S stock? Short selling NVZMY is an investing strategy that aims to generate trading profit from Novozymes A/S as its price is falling. NVZMY shares are trading up $0.74 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Novozymes A/S? A short squeeze for Novozymes A/S occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NVZMY, which in turn drives the price of the stock up even further. How often is Novozymes A/S's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NVZMY, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies argenx Short Squeeze BioNTech Short Squeeze Biogen Short Squeeze Moderna Short Squeeze Neurocrine Biosciences Short Squeeze Exelixis Short Squeeze Bio-Techne Short Squeeze Vaxcyte Short Squeeze Qiagen Short Squeeze Halozyme Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:NVZMY) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novozymes A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novozymes A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
